TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

Investing.com -- Shares of Tectonic Therapeutic, Inc. (NASDAQ ... that TX45 achieved a 17.9% reduction in Pulmonary Capillary Wedge Pressure (PCWP) across the study population.

Fukuda-san is perfectly bald, with a luxuriant mustache. His work has been described as “kind of British,” which means he ...

The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

"It was this weird, transcendental experience of it being what I needed to see and what it did to heal my own wounds," the 32-year-old described the acting gig as nothing short of therapeutic.